FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de peptides

HMG

Human Menopausal Gonadotropin / Menopur / Pergonal

Sexual Health

Human Menopausal Gonadotropin (HMG) is a urinary-derived preparation containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in approximately equal proportions, extracted and purified from the urine of postmenopausal women. It is FDA-approved for the treatment of infertility in both men and women, stimulating follicular development in women and spermatogenesis in men. Brand names include Menopur and Pergonal, and it remains a cornerstone of assisted reproductive technology.

Mécanisme d'action

Combination of FSH and LH extracted from post-menopausal urine. Directly stimulates ovarian follicular development (FSH component) and supports ovulation and corpus luteum function (LH component). Used in assisted reproduction protocols.

Protocoles de recherche

Pour des fins de recherche uniquement. Pas de conseil médical.

Fertility protocols use 75-150 IU daily via intramuscular injection, adjusted based on ovarian response monitoring. Male protocols for spermatogenesis use 75-150 IU 2-3 times weekly with HCG.

Notes de recherche

Clinical Research Status

HMG has been used in fertility medicine since the 1960s and holds FDA approval for ovulation induction in women with anovulatory infertility and for spermatogenesis stimulation in men with hypogonadotropic hypogonadism. Highly purified urinary HMG (Menopur) and recombinant alternatives (Gonal-F for FSH, Luveris for LH) provide different formulation options. Ongoing research compares urinary-derived versus recombinant gonadotropins for IVF outcomes.

Key Published Findings

Clinical trials demonstrate that HMG protocols produce equivalent or slightly superior IVF outcomes compared to recombinant FSH alone, possibly due to the LH component's contribution to follicular steroidogenesis. In male infertility, HMG combined with HCG can restore spermatogenesis in men with gonadotropin deficiency, with sperm appearing in ejaculate typically within 6-18 months. The LH activity in HMG supports theca cell androgen production necessary for optimal follicular development.

Safety Profile

Ovarian hyperstimulation syndrome (OHSS) is the most significant risk, ranging from mild (abdominal bloating) to severe (ascites, thromboembolism), requiring careful ultrasound and estradiol monitoring during stimulation cycles. Multiple pregnancy rates are elevated (15-25% in IUI cycles) due to multi-follicular development. In male patients, adverse effects are generally limited to gynecomastia and acne from increased testosterone and estrogen production.

Comparison to Related Compounds

Unlike recombinant FSH (follitropin alfa/beta), HMG contains both FSH and LH activity, providing a more complete gonadotropin stimulus. Compared to HCG which mimics only LH, HMG provides direct FSH stimulation critical for Sertoli cell function and spermatogenesis initiation. Highly purified HMG (Menopur) contains LH activity primarily from HCG co-purified from urine rather than true LH, though biological activity is equivalent.

Community Observations

Fertility specialists often debate the clinical significance of the LH component in HMG versus pure FSH protocols, with some evidence favoring HMG in specific patient populations (older women, poor responders). In male fertility protocols, HMG is typically added to HCG after initial testosterone normalization to specifically target spermatogenesis. Cost considerations remain relevant as urinary-derived preparations are generally less expensive than recombinant alternatives.

Moitié de vie

~24-48 hours

Réconstitution

Sterile diluent provided with kit

Conservation

Lyophilisé

Refrigerate 2-8C.

Réconstitué

Use immediately after reconstitution.

Statut légal aux États-Unis

FDA-approved (Rx only)

Autres noms connus

Human Menopausal GonadotropinMenopurPergonal

Questions fréquentes

Qu'est-ce que HMG ?

Human Menopausal Gonadotropin (HMG) is a urinary-derived preparation containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in approximately equal proportions, extracted and purified from the urine of postmenopausal women. It is FDA-approved for the treatment of infertility in both men and women, stimulating follicular development in women and spermatogenesis in men. Brand names include Menopur and Pergonal, and it remains a cornerstone of assisted reproductive technology.

Comment agit HMG ?

Combination of FSH and LH extracted from post-menopausal urine. Directly stimulates ovarian follicular development (FSH component) and supports ovulation and corpus luteum function (LH component). Used in assisted reproduction protocols.

Quel est le statut réglementaire de HMG aux États-Unis ?

FDA-approved (Rx only)

Quelle est la demi-vie de HMG ?

~24-48 hours

Sous quels autres noms HMG est-il connu ?

Human Menopausal Gonadotropin, Menopur, Pergonal

Peptide Contacts fournit des résumés basés sur la recherche à des fins d’information uniquement. Nous ne hébergeons, n’épandons ni ne recommandons les documents des fournisseurs. Toutes les certificats d'analyse, certificats GMP et communications du fournisseur doivent être demandés et vérifiés directement par l'acheteur. Rien sur cette plateforme ne constitue un avis juridique, médical ou professionnel. Les utilisateurs sont entièrement responsables de la vérification des informations du fournisseur et de l’assurance de la conformité avec toutes les lois locales, d'état et fédérales applicables avant l'achat de tout produit chimique de recherche. L'utilisation de cette plateforme constitue l'acceptation pleine et entière de la responsabilité personnelle.

Lire la déclaration complète